Back to Cell Types

JHH-2Homo sapiens (Human)Cancer cell line

Also known as: JHH2, Jhh-2

🤖 AI SummaryBased on 9 publications

Quick Overview

Human hepatocellular carcinoma cell line with p53 mutations and potential for drug sensitivity studies.

Detailed Summary

JHH-2 is a human hepatocellular carcinoma (HCC) cell line derived from liver tissue. It exhibits mutations in the p53 gene, which is a critical tumor suppressor involved in cell cycle regulation and apoptosis. These mutations may contribute to the malignant progression of the tumor. The cell line is utilized in research to study the molecular mechanisms of HCC, including the impact of p53 dysfunction on cancer development and therapeutic responses. JHH-2 is also part of large-scale studies examining copy number variations and gene expression profiles to identify potential biomarkers and therapeutic targets in liver cancer.

Research Applications

Molecular mechanisms of hepatocellular carcinomap53 gene mutations and cancer progressionDrug sensitivity and therapeutic response studies

Key Characteristics

p53 gene mutationsHepatocellular carcinoma originUsed in large-scale genomic and transcriptomic studies

Generated on 6/19/2025

Basic Information

Database ID	CVCL_2786
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age	57
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Adult hepatocellular carcinoma
Lineage	Liver
Subtype	Hepatocellular Carcinoma
OncoTree Code	HCC

DepMap Information

Source Type	HSRRB
Source ID	ACH-000577_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	c.375+2T>G (IVS4+2T>G)	Homozygous	Splice donor mutation	Unknown, Unknown, PubMed=31378681
MutationSimple	TERT	c.1-124C>T (c.228C>T) (C228T)	Unspecified	In promoter	from parent cell line Hep-G2
MutationSimple	CDKN2A	p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T)	Unspecified	-	PubMed=11787853

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

12,13

D13S317

12

D16S539

10,13

D18S51

13

D21S11

29,32.2

D3S1358

17

D5S818

9,13

D7S820

10

D8S1179

11,16

FGA

21,24

Penta D

10,13

Penta E

21

TH01

6,7

TPOX

8

vWA

14

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

A pharmacogenomic landscape in human liver cancers.";

Hui L.-J.

Cancer Cell 36:179-193.e11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.

Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.

Oncol. Rep. 6:1267-1271(1999).

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Fukaya K.-i., Ishioka C., Namba M.

Acta Med. Okayama 51:261-265(1997).

Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.

Kosaka T., Tsuji T., Namba M.

J. Med. Virol. 48:133-140(1996).

Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines.

Shimizu K., Niiya M., Kameda H., Fujita K., Ohno T.

Hepato-Gastroenterol. 37:457-460(1990).

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Ohashi R., Namba M.

Tissue Cult. Res. Commun. 16:173-178(1997).

Web Resources

lccl.zucmanlab.com tcpaportal.org